tbuckley/cabot-search huggingface dataset:
THE EFFECT OF DIAGNOSTIC ULTRASOUND MEDIATED SONOTHROMBOLYSIS APPLIED IMMEDIATELY AFTER EMERGENT PERCUTANEOUS CORONARY ARTERY INTERVENTION IN ACUTE LEFT ANTERIOR DESCENDING ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Arif Albulushi, Awail Sadiq, Khalid Al Saidi, Feng Xie, Lijun Qian, Gregory Pavlides, Edward O'Leary, David Barton, Andrew Goldsweig, Thomas Porter
Journal: Journal of the American College of Cardiology (2020)
How to become a doctor in the Royal Navy
Authors: Helen Jones
Journal: BMJ (2020)

As a doctor in the Royal Navy you will provide clinical care for some of the 35 000 men and women currently serving.

You will be expected to work in a range of challenging conditions at sea, on land, in the air, or beneath the waves in a submarine. You may be required to work in hostile situations and will be away from home for months at a time.

You will need to demonstrate outstanding leadership skills and have the ability to work as part of a tight knit team in difficult circumstances. But a career as a doctor in the navy provides adventure and overseas travel, and you will get to do things …
Outcomes consequent to “early” COPD for interventional studies
Authors: Yunus Çolak, Børge G. Nordestgaard, Jørgen Vestbo, Peter Lange, Shoaib Afzal
Journal: European Respiratory Journal (2020)

We thank S.I. Rennard for the interest in our study. We observed that individuals with chronic respiratory symptoms and normal spirometry had an increased risk of hospitalisations and death due to respiratory disease [1]. S.I. Rennard was particularly interested in estimating the sample size required for an intervention trial in individuals with early COPD based on the outcomes used in our study. Since COPD develops gradually over many years [2], identification of younger adults at high risk of developing COPD could lead to implementation of preventive measures before disease onset and thereby halt progression to improve long-term prognosis [3–5]. However, attempts to alter the natural history of COPD have mainly focused on lung function decline and development of chronic airflow limitation, rather than clinical outcomes such as respiratory hospitalisations or death. Power calculations for outcomes consequent to early COPD <http://bit.ly/30MrvCd>
Time to vulva cancer relapses in dependence on different factors.
Authors: Galina Nerodo, Victoria Aleksandrovna Ivanova, Ekaterina Alekseevna Nerodo
Journal: Journal of Clinical Oncology (2013)

e16513 Background: The time to relapses was investigated in dependence on different factors. Methods: We examined 809 vulva cancer patients to evaluate frequency and average time to relapse depending on grades, invasion depth and method of treatment. Results: We found out that 25.09% (203 from 809) of patients had a relapse. For the I grade the relapse was observed in 18.29% patients after 59.3 months on average, for the II grade – in 20.5% after 46.9 months, for the III grade – in 26.6% after 16.8 months, for the IV grade – in 46.2% patients after 7.2 months respectively. The patients of the II grade with tumor invasion of 1-2 mm had a relapse after 61.2 months, with invasion of 3-4 mm – after 42.1, with more than 5 mm – after 38.5 months on average correspondingly. For patients of the III grade with tumor invasion less than 5 mm the average time to relapse was 19.9 months, with invasion more than 5 mm – 12.6 months. There is not significant difference between the times to relapses of early grades patients treated with combined method or complex method with chemotherapy. However for the patients of the III grade the chemotherapy has prolonged the time to relapse from 13.5 to 18.1 months. Conclusions: The relapses of vulva cancer were observed in 25.09% of all patients. The grade, depth of invasion and chemotherapy as a part of complex treatment of III-IV grades patients have considerable influence on the time to relapse.
Estimation of Glomerular Filtration Rate With vs Without Including Patient Race
Authors: Andrew S. Levey, Hocine Tighiouart, Silvia M. Titan, Lesley A. Inker
Journal: JAMA Internal Medicine (2020)

This cross-sectional study evaluates the use of race in estimating glomerular filtration rate and whether height and weight could substitute for race using pooled data from 10 studies of people with and without chronic kidney disease.
Outcomes of patients with solitary plasmacytomas (SP) in the era of PET imaging and serum-free light chain (sFLC) testing: A single institution experience.
Authors: Abby L. Koch, Kenneth H. Shain, Melissa Alsina, Daniel Sullivan, Taiga Nishihori, Jose L. Ochoa-Bayona, Rachid C. Baz
Journal: Journal of Clinical Oncology (2013)

8608 Background: SP can occur in bone (SPB) or in extramedullary sites (EMP) and generally accounts for ~ 3-5% of plasma cell dyscrasias. Up to 50% of SPB and 15% of EMP will progress to multiple myeloma (MM). We evaluated the utility and prognostic significance of positron emission tomography (PET) imaging and SFLC ratio (sFLCr). Methods: We retrospectively reviewed electronic medical records of patients with SP evaluated at Moffitt Cancer Center between 1990-2012. The diagnosis of SP was per IMWG criteria (BJH 2003, 121:749) (biopsy proven single site, negative skeletal survey, bone marrow biopsy with no more than 10% plasma cells). Initial and post therapy sFLCr as well as PET findings were correlated with progression to symptomatic MM (PFS). Radiation therapy (XRT) was at the discretion of the treating physician. Results: 135 patients were identified and 91 (67%) were males. The median age was 58 years (range 20-82). Consistent with prior reports, the PFS of the entire cohort was 43 months (95% CI 17.8-70). 23 patients had PET prior to progression. All patients had uptake in the primary lesion (except 4 who had resection of the primary). 8 patients had additional PET findings in other bony structure (PET+), and 15 did not (PET-). 2 and 6 of the PET- and PET+ patients progressed (median PFS Not reached (NR) vs. 8.1 months, p=0.021) respectively. Of the 49 patients with available sFLC data, 32 had an abnormal ratio (17 progressed) and 17 patients had a normal ratio (2 progressed). Abnormal baseline sFLCr was associated with progression (median PFS 19 months vs NR, p=0.012). Post XRT, 44 patients had an available sFLCr, of which 23 had an abnormal ratio and 21 a normal ratio. A persistent serum/urine m spike after XRT was associated with progression to MM (median PFS 20.8 months vs NR, p&lt;0.0001). However, the association between Post XRT sFLCr and progression to MM was not statistically significant (median PFS 19 vs 43 months (abnormal vs normal ratio) p=0.2). Conclusions: PET imaging and sFLC are predictors of outcomes in SP and their routine inclusion in the diagnostic work up of patients with SP will result in a stage migration where patients outcomes are improved compared to historical controls.
A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)
Authors: P. Reichardt, P. G. Casali, J. Blay, M. Von Mehren, P. Schoffski, S. Hosseinzadeh, C. Tanaka, T. Gsponer, M. L. Veronese, G. D. Demetri
Journal: Journal of Clinical Oncology (2006)

9545 Background: Although imatinib induces durable clinical benefit in pts with metastatic GIST, resistance may emerge. AMN107 is a novel agent rationally designed to inhibit the PDGFR, KIT and Bcr-Abl tyrosine kinases. It has been shown to inhibit the proliferation of both imatinib-sensitive and imatinib-resistant GIST cells in vitro. Methods: Cohorts of imatinib-resistant GIST pts with radiological progressive disease (PD) were treated with AMN107 alone (400 mg p.o. bid) or with escalating doses of AMN107 (200 mg qd, 400 mg qd, or 400 mg bid) in combination with imatinib (400 mg p.o. bid). Pharmacokinetic (PK) analyses were performed for both AMN107 and imatinib. Serial tumor assessments included CT and 18FDG-PET scans. Results: As of 30 November 2005, 30 pts (13 women and 17 men), median age 51 yr (range 24–83) received AMN107 alone (n=18) or in combination up to 400 mg qd with imatinib (n=12) for 7 to 98 days (median 49 days). This study continues to accrue. Serious adverse events (SAE’s) reported in four patients deemed related to disease included abdominal pain, peritonitis and anemia. Grade 1/2 drug-related adverse events included hyperbilirubinemia, myalgias, peripheral edema and skin rash. Dose-limiting toxicity (Grade 3 elevated bilirubin) was reported in one pt on AMN107 alone. Efficacy data available for 18 patients show that three patients experienced progressive disease and 15 patients had stable disease, although the duration of follow-up was short. PK results in a limited number of patients showed that the effect of imatinib co-administration on AMN107 PK appears to be minimal, while AMN107 increases imatinib exposure on the average by 50%. Conclusions: AMN107 alone or in combination with imatinib has acceptable tolerability in patients with imatinib-resistant GIST. These initial data suggest there may be relevant activity of AMN107 alone and in combination with imatinib in imatinib-resistant metastatic GIST patients. [Table: see text]
IMPACT OF ACHIEVED AVERAGE SYSTOLIC BLOOD PRESSURE LEVELS ON FUTURE MORTALITY AMONG A REAL-WORLD POPULATION OF PATIENTS WITH HYPERTENSION
Authors: J. Brent Muhlestein, Benjamin Davies Horne, Nathan A. Allred, Erik R. Riessen, Raymond McCubrey, Heidi May, Charles J. Harrison, Kirk Knowlton, Jeffrey L. Anderson
Journal: Journal of the American College of Cardiology (2020)
Neutrophil to lymphocyte ratio as a prognostic indicator for advanced non-small cell lung cancer patients: A retrospective study.
Authors: Yanwen Yao, Dongmei Yuan, Hongbing Liu, Xiaoling Gu, Yong Song
Journal: Journal of Clinical Oncology (2012)

e18082 Background: Neutrophil to lymphocyte ratio (NLR) has been shown to be a prognostic indicator for different types of cancer. We aimed to investigate the prognostic significance of NLR in advanced non-small cell lung cancer (NSCLC) patients. Methods: From January 2007 to December 2010, total 201 patients who were histologically diagnosed NSCLC, staged for the TNM stage III or IV and chemotherapy-naïve were included. All patients were followed up until August 1st 2011. NLR was calculated from lymphocyte and neutrophil count on routine blood tests taken before diagnosis or first-line therapy. Results: The median survival time of all included patients was 354 days and mean value of NLR was 4.06. Cases were distributed into two groups at NLR value of 4.06. Multivariate analysis demonstrated that NLR was an independent and significant prognostic factor in overall survival (OS) (Hazard Ratio, HR=1.659, 95% Confidence Interval, CI=1.075-2.559, p=0.022). Conclusions: The results suggested that the elevated NLR predicted poor OS for advanced NSCLC patients. It may be a potential biomarker to stratify higher risk of death in advanced NSCLC patients, and this kind of patients may be supposed to more aggressive treatment to pursuit longer survival.
Decontamination of ambient RNA in single-cell RNA-seq with DecontX
Authors: Shiyi Yang, Sean E. Corbett, Yusuke Koga, Zhe Wang, W Evan Johnson, Masanao Yajima, Joshua D. Campbell
Journal: Genome biology (2020)

Abstract Droplet-based microfluidic devices have become widely used to perform single-cell RNA sequencing (scRNA-seq). However, ambient RNA present in the cell suspension can be aberrantly counted along with a cell’s native mRNA and result in cross-contamination of transcripts between different cell populations. DecontX is a novel Bayesian method to estimate and remove contamination in individual cells. DecontX accurately predicts contamination levels in a mouse-human mixture dataset and removes aberrant expression of marker genes in PBMC datasets. We also compare the contamination levels between four different scRNA-seq protocols. Overall, DecontX can be incorporated into scRNA-seq workflows to improve downstream analyses.
METABOLOMICS APPROACH TO THE ICD IMPLANTED PATIENT CHARACTERIZATION: A PILOT STUDY
Authors: Roberta Montisci, Luigi Barberini, Roberta Scotto, Claudia Fattuoni, Maria Francesca Marchetti, Garau Enrica, Dgrapov Dmitry, Andrea Montisci, Fulio Buonaguidi, Luigi Meloni
Journal: Journal of the American College of Cardiology (2020)
Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma
Authors: Md. Khadem Ali, Richard Y. Kim, Alexandra C. Brown, Jemma R. Mayall, Rafia Karim, James W. Pinkerton, Gang Liu, Kristy L. Martin, Malcolm R. Starkey, Amber L. Pillar, Chantal Donovan, Prabuddha S. Pathinayake, Olivia R. Carroll, Debbie Trinder, Hock L. Tay, Yusef E. Badi, Nazanin Z. Kermani, Yi-Ke Guo, Ritambhara Aryal, Sharon Mumby, Stelios Pavlidis, Ian M. Adcock, Jessica Weaver, Dikaia Xenaki, Brian G. Oliver, Elizabeth G. Holliday, Paul S. Foster, Peter A. Wark, Daniel M. Johnstone, Elizabeth A. Milward, Philip M. Hansbro, Jay C. Horvat
Journal: European Respiratory Journal (2020)

Accumulating evidence highlights links between iron regulation and respiratory disease. Here, we assessed the relationship between iron levels and regulatory responses in clinical and experimental asthma. We show that cell-free iron levels are reduced in the bronchoalveolar lavage (BAL) supernatant of severe or mild–moderate asthma patients and correlate with lower forced expiratory volume in 1 s (FEV 1 ). Conversely, iron-loaded cell numbers were increased in BAL in these patients and with lower FEV 1 /forced vital capacity (FVC) ratio. The airway tissue expression of the iron sequestration molecules divalent metal transporter 1 ( DMT1 ) and transferrin receptor 1 ( TFR1 ) are increased in asthma, with TFR1 expression correlating with reduced lung function and increased Type-2 (T2) inflammatory responses in the airways. Furthermore, pulmonary iron levels are increased in a house dust mite (HDM)-induced model of experimental asthma in association with augmented Tfr1 expression in airway tissue, similar to human disease. We show that macrophages are the predominant source of increased Tfr1 and Tfr1 + macrophages have increased Il13 expression. We also show that increased iron levels induce increased pro-inflammatory cytokine and/or extracellular matrix (ECM) responses in human airway smooth muscle (ASM) cells and fibroblasts ex vivo and induce key features of asthma in vivo , including airway hyper-responsiveness (AHR) and fibrosis, and T2 inflammatory responses. Together these complementary clinical and experimental data highlight the importance of altered pulmonary iron levels and regulation in asthma, and the need for a greater focus on the role and potential therapeutic targeting of iron in the pathogenesis and severity of disease.
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
Authors: L. Paz-Ares, A. Spira, D. Raben, D. Planchard, B.C. Cho, M. Özgüroğlu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, D. Spigel, S. Senan, C.J. Langer, B.A. Perez, A-M. Boothman, H. Broadhurst, C. Wadsworth, P.A. Dennis, S.J. Antonia, C. Faivre-Finn
Journal: Annals of Oncology (2020)
EARLY RECOVERY WITH SUCCESSFUL TRIPLETON PREGNANCY IN A CANCER SURVIVOR WITH LATE DOXORUBICIN-INDUCED CARDIOMYOPATHY AND POST ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)
Authors: Vanthana Bharathi, Mishita Goel, Xavier F. Pombar, Sunita Nathan, Tochi Okwuosa
Journal: Journal of the American College of Cardiology (2020)
Evaluation of factors related to late recurrence (later than 10 years after the primary treatment) in early breast cancer.
Authors: Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, Rumiko Tashima, Masahiro Nakano, Mamiko Fujisue, Yasuo Toyozumi, Nobuyuki Arima
Journal: Journal of Clinical Oncology (2013)

e11557 Background: Breast cancer is associated with a relatively good prognosis and heterogeneity. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence, later than 10 years after primary treatment, in early breast cancer. Methods: From 1980 to August 2012, 4774 patients who underwent primary treatment, including operation and estrogen and progesterone receptors (ER and PgR) measurement, were enrolled in this study. The patients were divided into two groups, those with a follow-up period within 10 years, and those (1323 patients) without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients within 10 years and occurred in 51 patients from ≥10 years. The items examined were tumor size, lymph node status, and biological markers such as ER, PgR, Ki-67 values, p53 and human epidermal growth factor receptor 2 (HER2) expressions. Results: The overall 10-year cumulative disease-free survival (DFS) rate was 79.5%, and the recurrence rate at ≥10 years was 5.8% (some cases had recurrence 20 years later). A multivariate analysis revealed that the factors related to late recurrence were positive nodes and PgR positive. This result differed from that for early recurrence, where the DFS rate was low in patients with ER/PgR negative, high Ki-67 index values and p53 overexpression. Conclusions: The PgR positivity and lymph node metastasis significantly correlated with late recurrence (later than 10 years after primary treatment) in early breast cancer. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive (ER and/or PgR positive) patients. In addition, how to inform patients about the recurrence rate and recurrence time from the initial treatment, and the Informed Consent regarding the follow-up period and surveillance plan must be examined.
Preoperative peripheral blood lymphocyte/monocyte ratio and survival in patients with resected stage IV melanoma.
Authors: Nicole M. Rochet, Luis F. Porrata, Lisa A. Kottschade, Travis Edward Grotz, Svetomir Markovic
Journal: Journal of Clinical Oncology (2012)

8600 Background: The prognosis of stage IV melanoma patients remains poor. Published results have suggested that components of the complete blood count have significant prognostic value in several malignancies. Among the most studied were the absolute lymphocyte count (ALC), and absolute monocyte count (AMC) on clinical outcomes of patients with lymphoid malignancies. Thus, we sought to investigate if the pre-operative ALC (ALC-PO), AMC (AMC-PO) and ALC/AMC ratio (ALC/AMC-PO) affects the risk of disease recurrence and survival after complete surgical resection of metastatic melanoma. Methods: We studied 66 stage IV, resected melanoma patients followed at Mayo Clinic from 2000 to 2010. Log rank chi-square analysis was used to determine the best cut-off values for each pre-operative variable, while proportional hazards models were used to compared survival. Results: The median follow-up of the cohort was 24 months (range: 2.3 – 117 months). ALC-PO, AMC-PO and ALC/AMC-PO, as continuous variables, were all identified as prognostic factors for both relapse-free survival (RFS) and overall survival (OS). The best cut-off values for ALC-PO, AMC-PO and ALC/AMC-PO were 1.9; 0.62; and 2.05, respectively. Using Kaplan-Meier analysis, patients with an ALC-PO ≥ 1.9 x 10 9 /L experienced superior OS and RFS compared with ALC-PO &lt; 1.9 x 10 9 /L patients [median OS of 58 months vs. 34 months, p &lt; 0.04; median RFS of 14 months vs. 5 months, p &lt; 0.009]. Conversely, a low AMC-PO (&lt;0.62 x 10 9 /L) was associated with better OS and RFS compared with higher AMC-PO (≥ 0.62 x 10 9 /L): [median OS of 47 months vs. 14 months, p &lt; 0.007; median RFS of 9 months vs. 5 months, p &lt; 0.02]. When the ALC-PO and AMC-PO were combined as an ALC/AMC ratio, the group with an ALC/AMC-PO ≥ 2.05 experienced a superior OS and RFS compared to patients with ALC/AMC-PO &lt; 2.05: [median OS of 49 months vs. 12 months, p &lt; 0.0001; median RFS of 10 months vs. 4 months, p &lt; 0.0001]. Multivariate analysis showed ALC/AMC-PO to be an independent prognostic factor for RFS and OS (HR = 0.32, p &lt; 0.003; HR = 0.23, p &lt; 0.002). Conclusions: Our study showed, that ALC/AMC-PO ratio is an independent prognostic factor for RFS and OS in patients undergoing resection of metastatic (stage IV) melanoma.
Toward an miRNA signature for predicting outcome in patients with melanoma.
Authors: Colette R Pameijer
Journal: Journal of Clinical Oncology (2013)

9039 Background: Melanoma remains a clinical challenge, as an aggressive and often unpredictable tumor. The incidence continues to increase, but treatment options are limited. One significant challenge is predicting which patients with stage I or II disease will have a poor outcome. We sought to develop a tool to assist in risk stratifying patients with melanoma. Methods: This is a prospective trial in which patients with melanoma at least 0.5mm deep were enrolled between 2007-2011. Tissue was collected from primary tumors, bulky nodes and metastatic deposits. RNA was extracted, labeled and hybridized to a miRNA microarray (Affymetrix). Hierarchical cluster method was used to find similarities among samples. A clinical patient database was maintained. Results: This study looks at 58 intermediate and high risk subjects. The median depth of melanoma was 3mm. The median age was 69 (range 26-95) and most patients (48/58, 83%) were treated with surgery alone, with ten receiving adjuvant therapy. All patients underwent wide excision, and 43 patients had sentinel node biopsy. Twenty-seven patients developed a recurrence (47%), and 19 (33%) patients have died, 14 from melanoma. The median length of follow-up is 21 months (range 1-76 months). A total of 112 probes are differentially expressed at a p value of 0.005. The largest number of differentially expressed probes relate to location of the tumor. Other significant differences are origin of the specimen (primary versus node), mitotic rate and subject age. High expression of miR-193b was correlated with death from melanoma, p=0.05. Parameters with no differential expression include gender, tumor depth and subtype, and ulceration. Conclusions: Microarray analysis of miRNAs is a reliable platform to obtain prognostic information about melanoma. The miRNA signatures found in this patient population reinforce some well described differences among patients with melanoma, and fail to find a difference between other groups thought to be clinically important. Tumor genetic profiling may provide better risk stratification of patients with melanoma than clinical parameters alone.
HYBRID OPERATION AS THERAPY TO LEFT VENTRICULAR DIVERTICULUM ACCOMPANIED WITH VENTRICULAR TACHYCARDIA
Authors: Tong Lan, Han-Xiong Liu, Lin Cai, Yong Luo, Xiao-Qi Deng, Duan Luo, Guo-Shu Yang, Yan-Feng Wang, Cui Zhang, Lian-Chao Cheng
Journal: Journal of the American College of Cardiology (2020)